Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to define the maximum tolerated dose of combination
docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects
will be measured in study participants. In addition, researchers will assess data about
preliminary efficacy in patients with this treatment approach.
Phase:
Phase 1
Details
Lead Sponsor:
Tony Bekaii-Saab
Collaborators:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center